C12N 2799/04
In vivo
Official title: in vivo
C12N2799/04 (In vivo) appears on 61 US grants and 104 published applications in this corpus.
Search patents in C12N- Granted patents
- 61
- Published applications
- 104
- Assignees
- 89
- Inventors
- 210
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 1 | 3 |
| 2005 | 1 | 3 |
| 2006 | 3 | 2 |
| 2007 | 1 | 5 |
| 2008 | 1 | 6 |
| 2009 | 3 | 9 |
| 2010 | 8 | 13 |
| 2011 | 2 | 12 |
| 2012 | 3 | 1 |
| 2013 | 7 | 4 |
| 2014 | 4 | 7 |
| 2015 | 2 | 3 |
| 2016 | 4 | 6 |
| 2017 | 3 | 5 |
| 2018 | 2 | 4 |
| 2019 | 3 | 4 |
| 2020 | 2 | 4 |
| 2021 | 3 | 4 |
| 2022 | 2 | 2 |
| 2023 | 2 | 2 |
| 2024 | 0 | 2 |
| 2025 | 2 | 1 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for the treatment of skin diseases16 Jun 2026US 12,655,447 B2Krystal Biotech, Inc.
- Gene therapy for ocular disorders2 Sep 2025US 12,403,204 B2The Trustees of the University of Pennsylvania
- Phagemid vector17 Jun 2025US 12,331,308 B2Imperial College Innovations Limited
- Synthetic promoters8 Aug 2023US 11,718,860 B2Massachusetts Institute of Technology
- Phagemid vector14 Mar 2023US 11,603,540 B2Imperial College Innovations Limited
- Constructs comprising neuronal viability factors and uses thereof20 Feb 2025US 2025/0059563 A1Inserm (Institut National De La Sante Et De La Recherche Medicale)
- Compositions and methods for treating sickle cell diseases24 Oct 2024US 2024/0352456 A1The United States of America, as represented by the Secretary, Department of Health and Human Services
- Compositions and methods for treating cancer11 Apr 2024US 2024/0115727 A1
- Phagemid Vector24 Aug 2023US 2023/0265452 A1Imperial College Innovations Limited
- Measles virus encoding a tumor antigen9 Mar 2023US 2023/0069933 A1Ruprecht-Karls-UniversitäT Heidelberg
Most cited
By later US patents
- Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes244US 8,389,282 B2Memorial Sloan Kettering Cancer Center · 2013
- Prosthetic grafts95US 6,328,762 B1Sulzer Biologics, Inc. · 2001
- Therapeutic methods and agents for diseases associated with decreased expression of AOP-1 gene or AOP-193US 7,598,228 B2Asubio Pharma Co., Ltd. · 2009
- Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes43US 9,220,728 B2Memorial Sloan Kettering Cancer Center · 2015
- Targeting agent for cancer cell or cancer-associated fibroblast32US 8,686,052 B2Nitto Denko Corporation · 2014